Clinically important nail psoriasis improvements are achieved with adalimumab (HUMIRA®):: results from a large open-label prospective study (STEREO)

被引：0
|
作者：
van den Bosch, F. [1 ]
Reece, R. [2 ]
Behrens, F. [3 ]
Wendling, D. [4 ]
Mikkelsen, K. [5 ]
Frank, M. [6 ]
Kron, M. [6 ]
Kupper, H. [6 ]
机构：
[1] Ghent Univ Hosp, B-9000 Ghent, Belgium
[2] Huddersfield Royal Infirm, Huddersfield, W Yorkshire, England
[3] Goethe Univ Frankfurt, Frankfurt, Germany
[4] Univ Franche Comte, F-25030 Besancon, France
[5] Hosp Rheumat Dis, Lillehammer, Norway
[6] Abbott GmbH & Co KG, Ludwigshafen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：421 / 421
页数：1
相关论文
共 50 条
  • [1] Adalimumab (Humira®) improves nail psoriasis in PsA:: results from large, open-label study (stereo)
    Van den Bosch, F.
    Reece, R.
    Behrens, F.
    Wendling, D.
    Mikkelsen, K.
    Frank, M.
    Kron, M.
    Kupper, H.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 51 - 52
  • [2] Treatment of nail psoriasis with adalimumab: an open label unblinded study
    Rigopoulos, D.
    Gregoriou, S.
    Lazaridou, E.
    Belyayeva, E.
    Apalla, Z.
    Makris, M.
    Katsambas, A.
    Ioannides, D.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (05) : 530 - 534
  • [3] Efficacy and safety of efalizumab for nail psoriasis: Results of an open-label, multicenter study
    Rich, Phoebe
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB130 - AB130
  • [4] PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE)
    Burmester, Gerd Ruediger
    Amital, Howard
    Rubbert-Roth, Andrea
    van Hoogstraten, Hubert
    Gervitz, Leonm.
    Thangavelu, Karthinathan
    St John, Gregory
    Genovese, Mark C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1138 - 1139
  • [5] Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study
    Patsatsi, Aikaterini
    Kyriakou, Aikaterini
    Sotiriadis, Dimitrios
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (02) : 96 - 100
  • [6] Treatment of nail psoriasis with brodalumab: an open-label unblinded study
    Gregoriou, S.
    Tsiogka, A.
    Tsimbidakis, A.
    Nicolaidou, E.
    Kontochristopoulos, G.
    Rigopoulos, D.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (04) : E299 - E301
  • [7] Adalimumab (Humira) for the Treatment of Refractory Sight-Threatening Non-Infectious Uveitis: Interim Results of an Open-Label Prospective Multicenter Study
    Suhler, E. B.
    Lowder, C. Y.
    Goldstein, D. A.
    Giles, T. R.
    Tessler, H. H.
    Lauer, A. K.
    Smith, J. R.
    Rosenbaum, J. T.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [8] Open-label, prospective evaluation of adalimumab for psoriasis patients who were nonresponders to etanercept
    Martyn-Simmons, C.
    Green, E.
    Ash, G.
    Groves, R.
    Smith, C. H.
    Barker, J. N. W. N.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (06) : 1425 - 1426
  • [9] Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study
    Morita, Akimichi
    Yamazaki, Fumikazu
    Matsuyama, Takashi
    Takahashi, Kenzo
    Arai, Satoru
    Asahina, Akihiko
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Hasegawa, Yuichi
    Williams, David
    Matsuda, Naoto
    Kitamura, Susumu
    [J]. JOURNAL OF DERMATOLOGY, 2018, 45 (12): : 1371 - 1380
  • [10] Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab
    Al-Mutairi, Nawaf
    Nour, Tarek
    Al-Rqobah, Duha
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) : 625 - 629
12345